ETFChannel.com
SGEN Description — Seattle Genetics Inc

Seattle Genetics is a biotechnology company that develops and commercializes therapies targeting cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, and PADCEV™, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Co. is developing ladiratuzumab vedotin, an antibody-drug conjugate targeting LIV-1, for patients with metastatic breast cancer and select solid tumors with high LIV-1 expression.

Company Name: 
Seattle Genetics Inc
Website: 
www.seattlegenetics.com
Sector: 
Biotechnology
Number of ETFs Holding SGEN: 
56
Total Market Value Held by ETFs: 
$1,911,957,425
Total Market Capitalization: 
$19,759,000,000
% of Market Cap. Held by ETFs: 
9.68%
 ETF   SGEN Weight   SGEN Amount 
 VTI   0.05%   $382,885,957         
 VO   0.40%   $345,662,580         
 QQQ   0.24%   $210,070,005         
 VXF   0.33%   $184,615,785         
 IBB   2.61%   $174,702,987         
 VUG   0.11%   $102,119,245         
 VOT   0.75%   $94,169,044         
 FBT   4.02%   $58,789,282         
 IWP   0.52%   $47,342,337         
 IWF   0.10%   $42,156,713         
List of all 56 ETFs holding SGEN »
Quotes delayed 20 minutes

Buy (2.94 out of 4)
33rd percentile
(ranked lower than approx. 67% of all stocks covered)

Analysts Forecast:
SGEN Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding SGEN | Seattle Genetics Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.